320 related articles for article (PubMed ID: 23443106)
1. Asymmetric dimethyarginine as marker and mediator in ischemic stroke.
Chen S; Li N; Deb-Chatterji M; Dong Q; Kielstein JT; Weissenborn K; Worthmann H
Int J Mol Sci; 2012 Nov; 13(12):15983-6004. PubMed ID: 23443106
[TBL] [Abstract][Full Text] [Related]
2. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes.
Tsikas D; Bollenbach A; Hanff E; Kayacelebi AA
Cardiovasc Diabetol; 2018 Jan; 17(1):1. PubMed ID: 29301528
[TBL] [Abstract][Full Text] [Related]
3. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke.
Schulze F; Carter AM; Schwedhelm E; Ajjan R; Maas R; von Holten RA; Atzler D; Grant PJ; Böger RH
Atherosclerosis; 2010 Feb; 208(2):518-23. PubMed ID: 19700158
[TBL] [Abstract][Full Text] [Related]
4. Serum asymmetric dimethylarginine and nitric oxide levels in Turkish patients with acute ischemic stroke.
Ercan M; Mungan S; Güzel I; Celik HT; Bal C; Abusoglu S; Akbulut D; Oguz EF; Yilmaz FM
Adv Clin Exp Med; 2019 May; 28(5):693-698. PubMed ID: 30170483
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?
Rochette L; Lorin J; Zeller M; Guilland JC; Lorgis L; Cottin Y; Vergely C
Pharmacol Ther; 2013 Dec; 140(3):239-57. PubMed ID: 23859953
[TBL] [Abstract][Full Text] [Related]
6. Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency.
Betz B; Möller-Ehrlich K; Kress T; Kniepert J; Schwedhelm E; Böger RH; Wanner C; Sauvant C; Schneider R
Transl Res; 2013 Aug; 162(2):67-76. PubMed ID: 23707198
[TBL] [Abstract][Full Text] [Related]
7. Arginine Derivatives in Cerebrovascular Diseases: Mechanisms and Clinical Implications.
Grosse GM; Schwedhelm E; Worthmann H; Choe CU
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32150996
[TBL] [Abstract][Full Text] [Related]
8. The impact of asymmetric dimethylarginine (ADAMA), the endogenous nitric oxide (NO) synthase inhibitor, to the pathogenesis of gastric mucosal damage.
Szlachcic A; Krzysiek-Maczka G; Pajdo R; Targosz A; Magierowski M; Jasnos K; Drozdowicz D; Kwiecien S; Brzozowski T
Curr Pharm Des; 2013; 19(1):90-7. PubMed ID: 22950506
[TBL] [Abstract][Full Text] [Related]
9. From arginine methylation to ADMA: a novel mechanism with therapeutic potential in chronic lung diseases.
Zakrzewicz D; Eickelberg O
BMC Pulm Med; 2009 Jan; 9():5. PubMed ID: 19178698
[TBL] [Abstract][Full Text] [Related]
10. Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition.
Wang Z; Tang WH; Cho L; Brennan DM; Hazen SL
Arterioscler Thromb Vasc Biol; 2009 Sep; 29(9):1383-91. PubMed ID: 19542023
[TBL] [Abstract][Full Text] [Related]
11. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy.
Bełtowski J; Kedra A
Pharmacol Rep; 2006; 58(2):159-78. PubMed ID: 16702618
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
Maas R
Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation.
Dayoub H; Rodionov RN; Lynch C; Cooke JP; Arning E; Bottiglieri T; Lentz SR; Faraci FM
Stroke; 2008 Jan; 39(1):180-4. PubMed ID: 18063827
[TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance.
Toutouzas K; Riga M; Stefanadi E; Stefanadis C
Horm Metab Res; 2008 Sep; 40(9):655-9. PubMed ID: 18792879
[TBL] [Abstract][Full Text] [Related]
15. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
Yamagishi S; Ueda S; Okuda S
Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
[TBL] [Abstract][Full Text] [Related]
16. High plasma dimethylarginine levels are associated with adverse clinical outcome after stroke.
Worthmann H; Chen S; Martens-Lobenhoffer J; Li N; Deb M; Tryc AB; Goldbecker A; Dong Q; Kielstein JT; Bode-Böger SM; Weissenborn K
J Atheroscler Thromb; 2011; 18(9):753-61. PubMed ID: 21566344
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor.
Böger RH
Cardiovasc Res; 2003 Oct; 59(4):824-33. PubMed ID: 14553822
[TBL] [Abstract][Full Text] [Related]
18. Asymmetric and Symmetric Dimethylarginines are Markers of Delayed Cerebral Ischemia and Neurological Outcome in Patients with Subarachnoid Hemorrhage.
Appel D; Seeberger M; Schwedhelm E; Czorlich P; Goetz AE; Böger RH; Hannemann J
Neurocrit Care; 2018 Aug; 29(1):84-93. PubMed ID: 29560598
[TBL] [Abstract][Full Text] [Related]
19. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke.
Yoo JH; Lee SC
Atherosclerosis; 2001 Oct; 158(2):425-30. PubMed ID: 11583722
[TBL] [Abstract][Full Text] [Related]
20. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA.
Sydow K; Hornig B; Arakawa N; Bode-Böger SM; Tsikas D; Münzel T; Böger RH
Vasc Med; 2004 May; 9(2):93-101. PubMed ID: 15521698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
